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Differentiating tissue stem cells can self-assemble into structures that strikingly resemble functional organ
subunits. Translating this insight to regenerative medicine presents several challenges.The concept of regenerative medicine
encompasses cell therapy, tissue engi-
neering, and improving the regenerative
capacity of endogenous organs. Three
major remaining obstacles to the clinical
application of stem cells are scaling up
production of progenitors, obtaining
mature (adult) human phenotypes in
terminally differentiated cells, and devel-
oping complex tissues. In this article we
discuss how knowledge about the mech-
anisms of cell proliferation, maturation,
and self-assembly could be used to
address these challenges and help realize
the therapeutic potential of stem cells.
Adult stem cells (more accurately called
‘‘tissue stem cells,’’ as they underlie tissue
self-renewal also during fetal, neonatal,
childhood, and adolescent development)
have been extensively studied and char-
acterized in vivo. However, with a few
exceptions the controlled in vitro develop-
ment of tissue stem cells has so far
proved elusive. Although there have
been impressive clinical successes with
transplantation of hematopoietic stem
cells (even without in vitro expansion),
scale-up will be essential for most other
stem cell clinical applications. The diffi-
culty of growing tissue stem cells
contrasts markedly with long-term prolif-
eration of cultured pluripotent stem cells.
Mouse embryonic stem cells (mESCs),
epiblast stem cells (EpiSCs), and human
embryonic stem cells (hESCs) have been
isolated from the embryo’s own pluripo-
tent cells, which proliferate actively both
before and after they undergo further
in vivo specialization. Despite their prolif-
erative capacity, however, the quantities
of pluripotent stem cells that can be ob-
tained in routine culture (108) are still
not sufficient for most clinical applications
if the stem cells are differentiated without
further cell proliferation. Moreover, in vitro
proliferation of pluripotent stem cell646 Cell Stem Cell 10, June 14, 2012 ª2012progeny typically ceases soon after the
induction of differentiation.
The requirement for scale-up focuses
attention on the possibility of expanding
cells in intermediate states between
stem cells and mature differentiation.
The in vitro counterpart of highly prolifera-
tive embryonic primary tissue layers
(the so-called ‘‘germ’’ layers—ectoderm,
endoderm, and mesoderm) would be a
valuable asset for achieving scale-up.
These could multiply the number of stem
cell progeny geometrically, just as
transit-amplifying or progenitor cells do
during normal tissue development and
homeostasis in vivo. The feasibility of
inducing mouse fibroblasts to become
neural stem cells has recently been
demonstrated (see Zhou and Tripathi,
2012), and endodermal progenitor cells
capable of differentiating into lung and
other tissues have now been derived
frommouse and human ESCs (see Kadzik
and Morrisey, 2012). Further studies will
be needed to see if mesodermal tissue
layer stem cells can also be captured
and to learn whether the differentiative
capacity of induced neural stem cells
and endodermal progenitor cells spans
the entire repertoire of their respective
primary tissue layers. In addition, studies
of the mechanisms regulating prolifera-
tion in stem cells and their differentiating
progeny will be important both for
achieving scale-up and for ensuring that
expanded cell populations do not
continue to proliferate inappropriately
once they are used for cellular therapies.
Although numerous protocols now
exist for inducing the differentiation of
mESCs, EpiSCs, hESCs, and induced
pluripotent stem cells (iPSCs) into specific
tissue fates, these differentiated cells
almost invariably correspond to an imma-
ture (fetal) rather than a fully mature (adult)
stage of development. This relative im-Elsevier Inc.maturity of pluripotent-stem-cell-derived
differentiated cells may compromise
their function and present a barrier to
engraftment and structural integration
into adult human tissues. Some evidence
may suggest that development of the
differentiated progeny of pluripotent cells
is accelerated as compared with mouse
or human fetal development, but their ulti-
mate phenotype is nonetheless immature.
In addition, normal organs contain not
only epithelial and mesenchymal cells,
but also vasculature, nerves, and fascia,
and the activity of all of these components
needs to be coordinated appropriately
to achieve organ function in vivo. Matura-
tion of all these different elements in vitro
might require months of differentiation-
promoting culture to generate fully
mature, organ-specific cell types from
pluripotent stem cells.
Recent work by van Vliet et al. (2010)
suggests an alternative strategy for
achieving mature phenotypes. They
identified a disparity between fetal and
adult progenitor cells in potential for
differentiation into mature cardiomyocyte
cells: fetal progenitors differentiated into
immature cardiomyocytes, whereas adult
progenitors formed mature ones. This
result indicates that the capacity for
maturation is acquired during in vivo
development from a pluripotent cell to
a tissue-specific progenitor. In addition,
recent studies that have demonstrated
reprogramming of differentiated mouse
cells directly from one phenotype to
another; these studies also provide
evidence that such ‘‘direct’’ reprogram-
ming can be achieved without transiting
a less mature state (see Vierbuchen and
Wernig, 2011). It may similarly be possible
to achieve mature human phenotypes by
direct reprogramming of mature cells.
However, it remains to be determined
what fundamentally distinguishes mature
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standing the transciptomic, proteomic,
and metabolomic networks that underlie
cell maturity should enable direct reprog-
ramming from highly proliferative pluripo-
tent or intermediate stem cells intomature
adult phenotypes, thus addressing both
the scale-up and maturity challenges.
The use of stem cells to generate entire
organs for transplantation to replace
diseased or damaged ones remains the
holy grail of regenerative medicine. It
may be possible in principle to generate
humanized organs in domestic species
using pluripotent stem cells and interspe-
cies chimeras, as has been done with
rats and mice. However, the ethical and
xenotransplantation obstacles inherent
in this approach make it very challenging.
Growing entire organs from embryonic
rudiments completely in vitro—recapitu-
lating the process of organ formation
and growth—seems equally if not more
difficult. An alternative to generating a
whole organ may be to generate the func-
tional subunits of an organ in vitro. Most
organs are composites of functional sub-
units (the smallest elements of an organ
that retain the essential activity performed
by the organ). For the kidney, this subunit
is the nephron; for the lung, the alveolus;
for the liver, the hepatic lobule; and for
the small intestine, the villus and crypt.
Recent research shows that it is possible
to generate functional organ subunits
from the differentiated progeny of tissue
stem cells. In these studies, self-orga-
nizing small intestine, stomach, and colon
epithelial structures (termed ‘‘organoids’’)
were generated from single, isolated
Lgr5+ endoderm cells. Importantly, a
recent study provides proof of principle
that organoids cultured from intestinal
stem cells can be used to repair damaged
colon epithelium (Yui et al., 2012). This
capacity for self-organization is not
limited to endodermal derivatives but
extends to both complex neuronal struc-
tures resembling hypophysis, retinal, and
cortical tissues and to mammary gland
epithelium (Eiraku and Sasai, 2012;
Chanson et al., 2011). Thus, at least
some tissue stem cells possess the
inherent capacity to achieve 3D
complexity when provided with relatively
simple biochemical information, even
without the multiple inputs that may occur
during embryonic organogenesis.This dramatic progress in achieving
self-assembly of functional organ sub-
units from isolated stem cells addresses
unresolved questions about the bio-
chemical nature of the inductive inter-
actions between tissue layers during
organogenesis. Information essential for
in vivo organogenesis comes from the
interactions between the epithelial and
mesenchymal components of the organ
rudiment. Classical studies of organo-
genesis regarded these interactions as
being either ‘‘permissive’’ or ‘‘instructive’’
depending on whether they could be
replaced with other tissues (e.g., induc-
tion of stomach endoderm development
by the mesenchyme layer from another
organ) (see Grapin-Botton, 2005). In
this light, the successful generation of
intestinal organoids implies that growth
factors, Matrigel, and the epithelial stem
cell progeny themselves can substitute
for both permissive and instructive
mesenchymal contributions once the
tissue stem cells have become specified.
Moreover, intestinal subunits can also be
generated from hESCs and human iPSCs
(Spence et al., 2011; see also Kadzik
and Morrisey, 2012), demonstrating that
the entire process of development from
pluripotency to organotypic function can
be ‘‘synthesized’’ in vitro.
The advent of stem-cell-derived
synthetic organs provides a great leap
forward for regenerative medicine. Tissue
engineers have previously assembled
dispersed cell populations onto man-
made biomaterials or decellularized
natural matrices as scaffolds to mimic
particular body structures (see Badylak
et al., 2012). The recent developments in
generating organ functional subunits
from tissue stem cells suggests focusing
attention instead on assembling func-
tional organ subunits into physiologically
relevant structures for use in extracorpo-
real support or for transplantation. It is
important to note that for practical appli-
cations such assemblies of functional
organ units need not have the appearance
of the normal organ if they nevertheless
recapitulate the organ’s functions.
Finally, recent studies have revolu-
tionized our concept of the origins
of phenotype, showing that pluripotent
stem cells, intermediate stem cells, or
mature differentiated cells can be induced
by expression of key components of theCell Stem Celltranscription factor network governing
state-specific gene expression. This
suggests that responsiveness to tran-
scription-factor-driven reprogramming is
inherent to many developmental states—
perhaps all of them. Could the mecha-
nisms underlying cellular self-assembly
into functional organ subunits be shared
across multiple organ systems? By
analogy with transcription-factor-driven
reprogramming, perhaps a relatively
small number of bioactive components
provided in vitro will be able to drive self-
assembly of different types of tissue
stem cells into their respective organ
subunits. Only time will tell whether this
scenario is in fact feasible, but, if it is, it
would imply that cellular phenotype and
organ subunit self-assembly programs
are actually embedded in the genetic
legacy of each species. Decoding these
programs would be a boon not only for
regenerative medicine, but also for under-
standing mechanisms of organogenesis,
particularly in humans.REFERENCES
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